Billiontoone (BLLN) Stock Price, News & Analysis

Company Overview

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics. Its technology aims to improve accuracy in detecting fetal aneuploidies, microdeletions, and single-gene disorders from maternal blood samples by reducing measurement noise and enabling precise digital quantification. The company provides testing services and partners with clinical laboratories, healthcare providers, and research organizations to implement its assays in clinical and research settings.

In support of clinical adoption, BillionToOne focuses on analytical validation, clinical studies, and building laboratory processes that integrate its single-molecule counting approach into standard diagnostic pipelines. The company positions its platform as complementary to existing sequencing and molecular methods, emphasizing improved detection of low-frequency variants and potential reductions in false positives that can drive follow-up invasive procedures.

BillionToOne serves the healthcare and clinical diagnostics market, primarily through collaborations and laboratory channels. Its management and scientific teams are oriented toward translating advanced genomic measurement techniques into deployable clinical tests, with ongoing efforts to expand the clinical utility and accessibility of its assays through partnerships and regulatory and clinical validation activities.

Key Stats

• Today's Range: $88.01 to $98.18
• 50-Day Range: $69.55 to $105.94
• 52-Week Range: $61.96 to $138.70
• Volume: 318,292 shs
• Average Volume: 400,076 shs
• Market Capitalization: $4.53 billion
• P/E Ratio: 179.09
• Dividend Yield: N/A
• Price Target: $125.29
• Consensus Rating: Moderate Buy

Billiontoone Stock Analysis - MarketRank™

Billiontoone scored higher than 93% of companies evaluated by MarketBeat, and ranked 6th out of 60 stocks in the services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Billiontoone has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Billiontoone has a consensus price target of $125.29, representing about 28.4% upside from its current price of $97.54.

Amount of Analyst Coverage

Billiontoone has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 15.05%

Earnings Growth

Earnings for Billiontoone are expected to grow by 15.05% in the coming year, from $0.93 to $1.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Billiontoone is 178.35, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.15.

Price to Earnings Ratio vs. Sector

The P/E ratio of Billiontoone is 178.35, which means that it is trading at a more expensive P/E ratio than the Services sector average P/E ratio of about 9.97.

Price to Book Value per Share Ratio

Billiontoone has a P/B Ratio of 8.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.19% of the float of Billiontoone has been sold short.

Short Interest Ratio / Days to Cover

Billiontoone has a short interest ratio ("days to cover") of 1.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Billiontoone has recently decreased by 36.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Billiontoone does not currently pay a dividend.

Dividend Growth

Billiontoone does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.40

News Sentiment

Billiontoone has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Services companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Billiontoone this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for BLLN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

6 people have added Billiontoone to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Billiontoone insiders have not sold or bought any company stock.

Percentage Held by Institutions

Billiontoone has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Services
• Industry: Services – Health
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BLLN
• CIK: 2070849
• Web: N/A
• Phone: (650) 460-2551
• Fax: N/A
• Employees: 620
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Billiontoone: $125.29
• High Price Target: $150.00
• Low Price Target: $90.00
• Potential Upside/Downside: +27.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 179.09
• Forward P/E Ratio: 105.91
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 10.92
• Quick Ratio: 10.58

Sales & Book Value

• Annual Sales: $305.11 million
• Price / Sales: 14.85
• Cash Flow: $0.38 per share
• Price / Cash Flow: 261.00
• Book Value: $10.99 per share
• Price / Book: 8.96

Miscellaneous

• Outstanding Shares: 45,990,000
• Free Float: N/A
• Market Cap: $4.53 billion
• Optionable: N/A
• Beta: N/A